Skip to main content
Clinical Trials/NCT03451526
NCT03451526
Completed
Not Applicable

A Multi-centre Real-world Non-interventional Observational Study to Compare Prognoses of the Chinese Patients With N2 Non-small Cell Lung Cancer Who Received Adjuvant Chemotherapies and Perioperative Chemotherapies After Surgeries

Tang-Du Hospital10 sites in 1 country2,929 target enrollmentDecember 1, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Non-small Cell Lung Cancer
Sponsor
Tang-Du Hospital
Enrollment
2929
Locations
10
Primary Endpoint
Overall survival
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The trial was designed to compare the effectiveness of radical resections of lung cancer plus adjuvant chemotherapies and perioperative chemotherapies in the patients with N2 non-small cell lung cancer

Detailed Description

The trial is a multi-centre real-world non-interventional observational study. The Chinese patients with N2 non-small cell lung cancer enrolled from 2014 to 2017 who received radical resections of lung cancer and adjuvant chemotherapies will be included in the study and the study data on patient demographic/tumor biological characteristics and clinical treatment will be collected to evaluate compare effectiveness of radical resection of lung cancer plus adjuvant chemotherapies and perioperative chemotherapies after surgeries.

Registry
clinicaltrials.gov
Start Date
December 1, 2017
End Date
March 30, 2018
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Tang-Du Hospital
Responsible Party
Principal Investigator
Principal Investigator

lixiaofei

Professor

Tang-Du Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients with radical resection of lung cancer enrolled from 2014 to 2019;
  • Pathologically diagnosed patients with non-small cell lung cancer;
  • Patients with age \> 18 years old;
  • Patients who did not receive chest surgeries before hospitalization;
  • Patients with N2 lymph nodes (+) after surgeries;
  • Patients who received lymphadenectomy for one group or more groups of lymph nodes;

Exclusion Criteria

  • Patients with second primary tumors or multiple primary tumors;

Outcomes

Primary Outcomes

Overall survival

Time Frame: 2014 - 2017

Overall survival

Secondary Outcomes

  • Disease-free survival(2014 - 2017)

Study Sites (10)

Loading locations...

Similar Trials